Jefferies Financial Group Comments on Enhabit, Inc.'s Q3 2022 Earnings (NYSE:EHAB) – MarketBeat


Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:

Enhabit, Inc. (NYSE:EHABGet Rating) – Analysts at Jefferies Financial Group issued their Q3 2022 earnings per share estimates for shares of Enhabit in a research report issued on Tuesday, August 30th. Jefferies Financial Group analyst B. Tanquilut anticipates that the company will post earnings per share of $0.33 for the quarter. Jefferies Financial Group has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Enhabit’s current full-year earnings is $1.50 per share. Jefferies Financial Group also issued estimates for Enhabit’s Q4 2022 earnings at $0.39 EPS, FY2022 earnings at $1.47 EPS, FY2023 earnings at $1.60 EPS and FY2024 earnings at $1.71 EPS.
Other equities analysts have also recently issued reports about the company. Credit Suisse Group began coverage on Enhabit in a research report on Thursday, August 25th. They set a “neutral” rating and a $19.00 price target on the stock. Bank of America began coverage on Enhabit in a report on Wednesday, July 13th. They issued an “underperform” rating and a $16.00 target price on the stock. Finally, Citigroup began coverage on Enhabit in a report on Thursday, August 18th. They issued a “neutral” rating and a $17.00 target price on the stock.

Enhabit Stock Performance

Shares of EHAB stock opened at $16.60 on Thursday. Enhabit has a 1 year low of $11.65 and a 1 year high of $25.25. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.41 and a current ratio of 1.41.

Institutional Trading of Enhabit

A number of institutional investors have recently bought and sold shares of EHAB. CI Investments Inc. acquired a new stake in Enhabit during the second quarter valued at $27,000. Millennium Management LLC acquired a new stake in Enhabit during the second quarter valued at $230,000. OLD Mission Capital LLC acquired a new stake in Enhabit during the second quarter valued at $379,000. Northern Trust Corp acquired a new stake in Enhabit during the second quarter valued at $494,000. Finally, Strs Ohio acquired a new stake in Enhabit during the second quarter valued at $3,262,000. Institutional investors and hedge funds own 28.68% of the company’s stock.

Insider Buying and Selling

In other Enhabit news, Director Charles M. Elson bought 3,700 shares of the firm’s stock in a transaction dated Thursday, August 11th. The stock was acquired at an average price of $13.55 per share, with a total value of $50,135.00. Following the completion of the transaction, the director now directly owns 22,069 shares in the company, valued at approximately $299,034.95. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Enhabit news, Director Leo I. Higdon, Jr. bought 4,500 shares of the firm’s stock in a transaction dated Wednesday, August 3rd. The stock was acquired at an average price of $13.57 per share, with a total value of $61,065.00. Following the completion of the transaction, the director now directly owns 4,500 shares in the company, valued at approximately $61,065. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Charles M. Elson bought 3,700 shares of the firm’s stock in a transaction dated Thursday, August 11th. The stock was acquired at an average cost of $13.55 per share, with a total value of $50,135.00. Following the transaction, the director now owns 22,069 shares of the company’s stock, valued at $299,034.95. The disclosure for this purchase can be found here. Insiders have purchased 46,942 shares of company stock worth $645,314 in the last three months.

Enhabit Company Profile

(Get Rating)
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Enhabit, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Enhabit wasn’t on the list.
While Enhabit currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Tom remains optimistic about investors’ prospects going forward, even as the market reacts to the words of Fed Chair Jerome Powell about “pain ahead.”
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

source


Leave a Reply

Your email address will not be published.